The mitochondrial pyruvate carrier complex potentiates the efficacy of proteasome inhibitors in multiple myeloma

Multiple myeloma (MM) is a hematological malignancy that emerges from antibody-producing plasma B cells. Proteasome inhibitors, including the US Food and Drug Administration–approved bortezomib (BTZ) and carfilzomib (CFZ), are frequently used for the treatment of patients with MM. Nevertheless, a si...

Descripción completa

Detalles Bibliográficos
Autores principales: Findlay, Steven, Nair, Remya, Merrill, Ronald A., Kaiser, Zafir, Cajelot, Alexandre, Aryanpour, Zahra, Heath, John, St-Louis, Catherine, Papadopoli, David, Topisirovic, Ivan, St-Pierre, Julie, Sebag, Michael, Kesarwala, Aparna H., Hulea, Laura, Taylor, Eric B., Shanmugam, Mala, Orthwein, Alexandre
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Myeloid Neoplasia
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10362273/
https://www.ncbi.nlm.nih.gov/pubmed/36920785
http://dx.doi.org/10.1182/bloodadvances.2022008345

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10362273/
https://www.ncbi.nlm.nih.gov/pubmed/36920785
http://dx.doi.org/10.1182/bloodadvances.2022008345

Ejemplares similares